$ALT
Altimmune Inc Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000114420414028677 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$676.00	$3.740M	$6.480M
YoY Change	-59.18%	-42.28%	5.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.420M	$2.680M	$2.280M
YoY Change	3.86%	17.54%	-22.71%
% of Gross Profit
Research & Development	$2.373M	$3.427M	$5.233M
YoY Change	-30.27%	-34.52%	11.22%
% of Gross Profit
Depreciation & Amortization	$36.21K	$39.94K	$52.60K
YoY Change	-13.49%	-24.07%	-41.55%
% of Gross Profit
Operating Expenses	$4.829M	$6.144M	$7.566M
YoY Change	-16.42%	-18.79%	-2.25%
Operating Profit	-$1.170M	-$2.402M	-$1.091M
YoY Change	-21.05%	120.21%	-31.43%
Interest Expense	$56.55K	$69.87K	$99.79K
YoY Change	-43.46%	-29.98%	3195.61%
% of Operating Profit
Other Income/Expense, Net	$724.1K	$173.1K	-$1.011M
YoY Change	182.22%	-117.13%	7.68%
Pretax Income	-$445.8K	-$2.229M	-$2.102M
YoY Change	-63.61%	6.05%	-16.91%
Income Tax	-$10.00K	$30.00K	$9.743K
% Of Pretax Income
Net Earnings	-$439.1K	-$2.258M	-$2.111M
YoY Change	-64.48%	6.96%	-21.21%
Net Earnings / Revenue	-64958.58%	-60.39%	-32.58%
Basic Earnings Per Share	-$0.01	-$0.04	-$0.04
Diluted Earnings Per Share	-$0.01	-$0.04	-$0.04
COMMON SHARES
Basic Shares Outstanding	54.48M shares	53.04M shares	48.37M
Diluted Shares Outstanding		53.04M shares

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.30M	$9.500M	$12.90M
YoY Change	-28.48%	-26.36%	-15.69%
Cash & Equivalents	$11.27M	$9.535M	$12.87M
Short-Term Investments	$6.400M	$6.400M
Other Short-Term Assets	$600.0K	$400.0K	$600.0K
YoY Change	-14.29%	-33.33%	-25.0%
Inventory
Prepaid Expenses
Receivables	$600.0K	$1.600M	$5.600M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.43M	$11.59M	$19.07M
YoY Change	-42.68%	-39.24%	-11.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$386.5K	$380.6K	$456.8K
YoY Change	-15.99%	-16.7%	-34.92%
Goodwill	$2.348M	$2.348M	$2.348M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$55.03K	$59.13K	$99.58K
YoY Change	-35.94%	-40.62%	-42.94%
Total Long-Term Assets	$2.790M	$2.788M	$2.905M
YoY Change	-3.61%	-4.02%	-9.93%
TOTAL ASSETS
Total Short-Term Assets	$12.43M	$11.59M	$19.07M
Total Long-Term Assets	$2.790M	$2.788M	$2.905M
Total Assets	$15.22M	$14.37M	$21.97M
YoY Change	-38.08%	-34.58%	-11.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$437.4K	$471.8K	$1.290M
YoY Change	-85.38%	-63.42%	-8.57%
Accrued Expenses	$1.400M	$1.900M	$3.300M
YoY Change	-33.33%	-42.42%	13.79%
Deferred Revenue
YoY Change
Short-Term Debt			$1.329M
YoY Change			54.96%
Long-Term Debt Due	$1.000M	$1.000M	$1.000M
YoY Change	0.0%	0.0%	411.74%
Total Short-Term Liabilities	$2.831M	$3.465M	$7.788M
YoY Change	-63.34%	-55.5%	46.55%
LONG-TERM LIABILITIES
Long-Term Debt	$239.7K	$485.4K	$1.460M
YoY Change	-80.31%	-66.76%	-34.65%
Other Long-Term Liabilities	$572.9K	$602.4K	$580.2K
YoY Change	-0.84%	3.82%	4.36%
Total Long-Term Liabilities	$812.6K	$1.088M	$2.041M
YoY Change	-54.74%	-46.69%	-26.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.831M	$3.465M	$7.788M
Total Long-Term Liabilities	$812.6K	$1.088M	$2.041M
Total Liabilities	$4.359M	$6.049M	$12.03M
YoY Change	-61.65%	-49.72%	9.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$213.0M	-$212.6M	-$200.7M
YoY Change	5.48%	5.91%	2.22%
Common Stock	$224.1M	$221.1M	$210.9M
YoY Change	4.04%	4.86%	0.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.86M	$8.325M	$9.943M
YoY Change
Total Liabilities & Shareholders Equity	$15.22M	$14.37M	$21.97M
YoY Change	-38.08%	-34.58%	-11.24%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$439.1K	-$2.258M	-$2.111M
YoY Change	-64.48%	6.96%	-21.21%
Depreciation, Depletion And Amortization	$36.21K	$39.94K	$52.60K
YoY Change	-13.49%	-24.07%	-41.55%
Cash From Operating Activities	-$540.0K	-$2.294M	$260.4K
YoY Change	10.2%	-980.97%	-67.09%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	$37.05K	$25.47K
YoY Change	0.0%	45.48%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$10.00K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$40.00K	-$29.05K	-$25.47K
YoY Change	0.0%	14.06%	-137.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$2.719M	$53.41K
YoY Change		4990.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.300M	$1.377M	-$60.36K
YoY Change	-33.53%	-2382.01%	-101.88%
NET CHANGE
Cash From Operating Activities	-540.0K	-$2.294M	$260.4K
Cash From Investing Activities	-40.00K	-$29.05K	-$25.47K
Cash From Financing Activities	2.300M	$1.377M	-$60.36K
Net Change In Cash	1.720M	-$945.7K	$174.6K
YoY Change	-41.3%	-641.71%	-95.7%
FREE CASH FLOW
Cash From Operating Activities	-$540.0K	-$2.294M	$260.4K
Capital Expenditures	-$40.00K	$37.05K	$25.47K
Free Cash Flow	-$500.0K	-$2.331M	$234.9K
YoY Change	11.11%	-1092.25%	-70.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	dei	Trading Symbol TradingSymbol	PIP
CY2014Q1	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1929379	USD
CY2013Q4	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3182687	USD
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54476138	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12600000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600000	shares
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	PHARMATHENE, INC
CY2014Q1	us-gaap	Assets Assets	14374221	USD
CY2013Q4	us-gaap	Assets Assets	17139289	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	11586064	USD
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	pip	Billed And Unbilled Accounts Receivable Net BilledAndUnbilledAccountsReceivableNet	1600000	USD
CY2014Q1	pip	Long Term Debt Excluding Discount LongTermDebtExcludingDiscount	1500004	USD
CY2014Q1	pip	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate	0.12	pure
CY2009Q3	pip	Warrant Expiration Date WarrantExpirationDate	2015-01-28
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	471803	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1128172	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-219367	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-218710	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	221125757	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	217877117	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	528878	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328581	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	14339108	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-946259	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	171894	USD
CY2014Q1	us-gaap	Billed Contract Receivables BilledContractReceivables		USD
CY2013Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	1427113	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9534720	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10480979	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12873411	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12701517	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2013Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53773705	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52304426	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53773705	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52304426	shares
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	5377	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	5230	USD
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	3742525	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	6475138	USD
CY2014Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29705	USD
CY2013Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9743	USD
CY2012Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2500000	USD
CY2014Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	1497594	USD
CY2013Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1740235	USD
CY2013Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2201390	USD
CY2012Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1295613	USD
CY2014Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2018	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	51663	USD
CY2014Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1495576	USD
CY2013Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1688572	USD
CY2014Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	29705	USD
CY2013Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9743	USD
CY2014Q1	us-gaap	Deferred Revenue DeferredRevenue	62261	USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	341723	USD
CY2014Q1	us-gaap	Depreciation Depreciation	39939	USD
CY2013Q1	us-gaap	Depreciation Depreciation	52602	USD
CY2014Q1	us-gaap	Derivative Assets DerivativeAssets	6428787	USD
CY2013Q4	us-gaap	Derivative Assets DerivativeAssets	7928807	USD
CY2014Q1	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	2018	USD
CY2013Q4	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	51663	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-590	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2678	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2300000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	5393	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2677452	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2279795	USD
CY2014Q1	us-gaap	Goodwill Goodwill	2348453	USD
CY2013Q4	us-gaap	Goodwill Goodwill	2348453	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2228735	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2101642	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-60361	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29050	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25468	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2294064	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	260401	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-656373	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-407653	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1427113	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-566725	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1274906	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	950800	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-279462	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-507351	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	178704	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39486	USD
CY2014Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-549629	USD
CY2013Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-400645	USD
CY2014Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-69872	USD
CY2013Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-99008	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	43287	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	67360	USD
CY2014Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	6428787	USD
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	7928807	USD
CY2014Q1	us-gaap	Liabilities Liabilities	6048819	USD
CY2013Q4	us-gaap	Liabilities Liabilities	9803577	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14374221	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17139289	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3465457	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6795981	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	1485384	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	999996	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	999996	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	750007	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	749997	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	485388	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	730279	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1377445	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	602398	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	588745	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	362	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6123	USD
CY2014Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	26591	USD
CY2013Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	32431	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2258440	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-2111385	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	173131	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1010908	USD
CY2014Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	6144391	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	7565872	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2401866	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1090734	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	59132	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	65660	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-657	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1684	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2259097	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2113069	USD
CY2014Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		USD
CY2013Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	112500	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37050	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25468	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	401448	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	231491	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2719184	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53413	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1091740	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1274	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-249999	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt		USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	8000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	380572	USD
CY2014Q1	us-gaap	Short Term Borrowings ShortTermBorrowings		USD
CY2013Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1091740	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	8325402	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	386068	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3427000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5233475	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212586365	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210327925	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	528878	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	328581	USD
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1217755	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	60000	shares
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	7335712	USD
CY2014Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	1649896	USD
CY2013Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2199525	USD
CY2014Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	242641	USD
CY2013Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-905777	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Use of Estimates</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in">  </p> <!--EndFragment--></div> </div>
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53044119	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48359181	shares

Files In Submission

Name	View Source	Status
0001144204-14-028677-index-headers.html	Edgar Link	pending
0001144204-14-028677-index.html	Edgar Link	pending
0001144204-14-028677.txt	Edgar Link	pending
0001144204-14-028677-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
pip-20140331.xml	Edgar Link	completed
pip-20140331.xsd	Edgar Link	pending
pip-20140331_cal.xml	Edgar Link	unprocessable
pip-20140331_def.xml	Edgar Link	unprocessable
pip-20140331_lab.xml	Edgar Link	unprocessable
pip-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v376166_10q.htm	Edgar Link	pending
v376166_ex31-1.htm	Edgar Link	pending
v376166_ex31-2.htm	Edgar Link	pending
v376166_ex32-1.htm	Edgar Link	pending
v376166_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune Inc Stock $alt

2014 Q2 Form 10-Q Financial Statement

#000114420414028677 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune Inc Stock $alt

2014 Q2 Form 10-Q Financial Statement

#000114420414028677 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune Inc Stock $alt